 The purpose of the work is to audit the affordability of oral GLDs for the treatment of type II diabetes, which are subject to reimbursement under the state program in Ukraine and to study their availability. The research found that only three drugs under the INN are subject to reimbursement, metformin, glibanglamide, and glycloside. Metformin, glycloside, and glibanglamide tablets are available in sufficient assortment of different dosages and packaging. The copayments for DDD ranges from UAH 0.111 to UAH 2.510 for glycloside, and from UAH 0.105 to UAH 1.576 for metformin. To increase the affordability of GLDs and the introduction of modern treatment schemes, it is necessary to expand the list of reimbursable GLDs, including prolonged forms of metformin and innovative drugs such as GLP1 and SGLT2. This article was authored by I. Ovalosenko.